Drug news

IDX 184 (Idenix) in Phase II for Hepatitis C

Read time: 1 mins

Last updated:22nd Jun 2012

Published:22nd Jun 2012

Source: Pharmawand

Idenix Pharmaceuticals has reported positive data from both an interim analysis of a Phase II study of its drug candidate for Hepatitis C virus , IDX184. The company plans to begin a combination study of the IDX 184 and IDX 719, which has just completed a proof of concept study, by the end of the year.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news